|Date Added:||26 February 2007|
|File Size:||44.25 Mb|
|Operating Systems:||Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X|
|Price:||Free* [*Free Regsitration Required]|
There have been reports of abuse of cyclizine, either oral or intravenous, for its euphoric or hallucinatory effects. General disorders and administration site conditions. Each pack contains 5 or 10 ampoules. Why not subscribe to the newsletter? Active ingredient cyclizine lactate.
This article is for information only and should not be used for the diagnosis or treatment of medical conditions. The relevance of these studies to the human situation is not known.
Cyclizine Lactate 50 mg/ml Solution for Injection
R06AE03 Mechanism of action: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. However, long-term studies with cyclizine administered with nitrate have indicated no carcinogenicity. For instructions on dilution of the medicinal product before administration, see section 6.
Anaphylaxis has been recorded following intravenous administration of cyclizine co-administered with propanidid in the same syringe. When used intravenously, Cyclizine Injection should be injected slowly cyclixine the bloodstream, with only minimal withdrawal of blood into the syringe.
Eye disorders Blurred vision, oculogyric crisis. Marketing syrige number s 9. To view the changes to a medicine you must sign up and log in.
Cyclizine may have a hypotensive effect. Used for confusion with evidence of hallucinations. Cyclizine given intravenously, in half the recommended dose, increases the syirnge oesophageal sphincter tone and thereby reduces the hazard of regurgitation and aspiration of gastric contents if given to patients, undergoing emergency surgery, before induction of general anaesthesia.
Convulsions should be controlled in the usual way with parenteral anticonvulsant therapy. Some animal studies are interpreted as indicating that cyclizine may be teratogenic at dose levels up to 25 times the clinical dose level. The solution should be examined visually following dilution and immediately prior to administration and should not be used if any cloudiness or particulate matter is present.
Cyclizine Lactate 50 mg/ml Injection – Summary of Product Characteristics (SmPC) – (eMC)
Epilepsy ; glaucoma in children ; may counteract haemodynamic benefits of opioids ; neuromuscular disorders—increased risk of transient paralysis with intravenous use ; prostatic hypertrophy in adults ; pyloroduodenal obstruction ; severe heart failure—may cause fall in cardiac output and associated increase in heart rate, mean arterial pressure and pulmonary wedge pressure ; susceptibility to angle-closure glaucoma in adults ; urinary retention.
Breast-feeding Cyclizine is excreted in human milk, however, the amount has not been quantified. Hepatic dysfunction see section 4. Although GPs provide the majority of palliative care services in the UK, there are often problems with symptom control and communication. For the prevention of postoperative nausea and vomiting, administer the first dose by slow intravenous injection 20 minutes before the anticipated end of surgery.
Hepatobiliary disorders Not known Hepatic dysfunction see section 4. Abdominal pain ; agranulocytosis ; angioedema ; anxiety ; apnoea ; appetite decreased ; arrhythmias ; asthenia ; bronchospasm ; constipation ; diarrhoea ; disorientation ; dizziness ; drowsiness ; dry mouth ; dry throat ; euphoric mood ; haemolytic anaemia ; hallucinations ; headache ; hepatic disorders ; hypertension ; hypotension ; increased gastric reflux ; insomnia ; leucopenia ; movement disorders ; muscle complaints ; nasal dryness ; nausea ; oculogyric crisis ; palpitations ; paraesthesia ; photosensitivity reaction ; seizure ; skin reactions ; speech disorder ; thrombocytopenia ; tinnitus ; tremor ; urinary retention ; vision blurred ; vomiting.
Adverse reactions are ranked under heading of frequency, the most frequent first, vyclizine the following convention: Carcinogenicity No long term studies have been conducted in animals to determine whether cyclizine has a potential for carcinogenesis.
Assess your symptoms online with our free symptom checker.